P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 31; p. S114
Main Authors: Lordick, F., Orra, E. Buxó, Cervantes, A., Dayyani, F., Rocha-Lima, C., Greil, R., Laarhoven, H. van, Lorenzen, S., Kischel, R., Shitara, K., Chao, J.
Format: Journal Article
Language:English
Published: 01-07-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2020.04.158